The short answer: tirzepatide produced larger average weight reduction than semaglutide in the trials, including in a direct head-to-head comparison. That does not make it the right medication for everyone. Tolerability, medical history, cost and availability all shift the decision, and for a substantial number of people semaglutide is the better fit.
Neither is a medication you choose for yourself from an article. What this page can do is explain what the difference actually is, so your consultation starts further along.
Which brand names treat weight?
This trips people up more than the mechanism does. Semaglutide and tirzepatide are the drug molecules. They are sold under four brand names, and two of those are approved for weight.
| Brand | Molecule | FDA-approved for |
|---|---|---|
| Wegovy | Semaglutide | Weight reduction in obesity, or overweight with a weight-related condition |
| Zepbound | Tirzepatide | Weight reduction in obesity, or overweight with a weight-related condition, and obstructive sleep apnea with obesity |
| Ozempic | Semaglutide | Type 2 diabetes |
| Mounjaro | Tirzepatide | Type 2 diabetes |
If a provider prescribes Ozempic or Mounjaro for weight loss, that is off-label prescribing. It is lawful and sometimes appropriate, and it should be named out loud rather than blurred. We name it.
What do they have in common?
Both are weekly self-administered injections. Both work substantially by slowing gastric emptying and acting on appetite regulation in the brain, which is why people describe the effect as food simply occupying less of their attention rather than as forced restriction.
Both are titrated slowly. Wegovy starts at 0.25 mg weekly and steps up roughly every four weeks toward a 2.4 mg maintenance dose (Wegovy label). Zepbound starts at 2.5 mg weekly and steps up in 2.5 mg increments after every four weeks toward 5, 10 or 15 mg (Zepbound label). Starting low and going slowly is how the first weeks stay comfortable.
Both work considerably better alongside sustained changes to nutrition and movement than they do alone.
How does each one work?
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after eating that signals fullness, slows stomach emptying and moderates blood sugar. It binds that one receptor and holds the signal on for roughly a week per dose.
Tirzepatide is a dual agonist. FDA labeling describes it as a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist. It acts on the same GLP-1 receptor and also on the GIP pathway, a second gut hormone route involved in insulin response and fat metabolism. Engaging both appears to produce a larger metabolic effect, which is the mechanistic explanation for the difference in trial results.
That is the structural difference. Everything else, including weekly dosing and slow titration, is broadly shared.
What did the trials find?
Both were studied in large randomised trials alongside lifestyle support. The figures below are averages across thousands of participants over roughly a year and a half.
- Semaglutide at the 2.4 mg weight-management dose produced mean weight reduction of 14.9% over 68 weeks in STEP-1, in 1,961 participants (Wilding et al., New England Journal of Medicine). Eighty-six percent of participants lost at least 5% of body weight.
- Tirzepatide produced mean reductions of 16.0%, 21.4% and 22.5% at its 5, 10 and 15 mg doses over 72 weeks in SURMOUNT-1, in 2,539 participants.
- Head to head, SURMOUNT-5 compared the two directly in 751 adults over 72 weeks, with mean weight change of 20.2% on tirzepatide and 13.7% on semaglutide (Aronne et al., New England Journal of Medicine).
Read those numbers as averages. They came from people who met trial criteria, at maximum tolerated doses, with structured lifestyle support, over long periods. Individual results vary widely in both directions.
One nuance almost nobody mentions. SURMOUNT-5 capped semaglutide at 2.4 mg, the maximum approved dose when the trial ran. The Wegovy label was updated in June 2026 to permit escalation to 7.2 mg where tolerated, and no head-to-head has compared tirzepatide against that higher dose.
Side by side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Weight-approved brand | Wegovy | Zepbound |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Administration | Weekly injection | Weekly injection |
| Titration | 0.25 mg, stepping up about every 4 weeks | 2.5 mg, stepping up every 4 weeks |
| Maintenance dose | 2.4 mg, up to 7.2 mg if tolerated | 5, 10 or 15 mg |
| Trial average | 14.9% over 68 weeks (STEP-1) | 16.0 to 22.5% by dose over 72 weeks (SURMOUNT-1) |
| Head-to-head result | 13.7% | 20.2% |
Why isn't the stronger option automatically the right one?
Several real reasons:
- Tolerability. A medication you can stay on comfortably is the one that works for you, whatever the averages say. Some people do noticeably better on one than the other.
- You may not need the ceiling. If your goal is a moderate reduction, reaching it comfortably on a lower-intensity option beats pushing a stronger one.
- Cost. There is usually a meaningful price difference, and a plan you can sustain for a year beats a better plan you stop after three months.
- Availability. Supply shapes what is obtainable, and that legitimately affects what gets prescribed.
- Your medical history. Other conditions, medications and prior response all bear on the choice.
The best medication is the one you can tolerate, afford, and stay on long enough for it to matter.
What should you expect in the first weeks?
Most people notice some gastrointestinal effects early, usually nausea, sometimes changes in bowel habit. These typically settle as your body adjusts, and easing the dose increase is the usual and entirely normal response.
Rapid dose escalation is the most avoidable cause of a rough start, which is why the titration schedule is deliberately slow. Monthly check-ins exist so adjustments happen when you need them rather than at your next refill.
Muscle matters too. Some of what you lose is lean tissue, in roughly the proportion seen with any diet-driven weight loss (Rossi et al., Acta Diabetologica). That is why protein targets, resistance training and body composition testing are part of the plan rather than an afterthought.
Is this long-term?
Yes, and knowing that up front makes the plan better.
Obesity is managed the way other chronic conditions are, and continuing treatment is what compounds the result. In SURMOUNT-4, participants who had lost 20.9% over 36 weeks and stayed on treatment reached 26.0% total mean weight loss by week 88 (Aronne et al., JAMA).
When to titrate, when to hold, and what maintenance looks like belong in your monthly check-ins from the beginning.
What we'll talk about at your consult
- Your history, current health, labs and goals.
- Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, which rules out this class.
- Pregnancy or plans for it, since these medications are stopped in pregnancy and at least two months before trying.
- Any other GLP-1 medication, which is not combined with these.
- Gallbladder and pancreatic history, and how we monitor.
Both carry a boxed warning relating to thyroid C-cell tumors seen in rodents, and we go through that with you directly.
Questions worth asking any provider
The same questions in our guide to choosing a practice, applied to this program:
- Will I have in-person clinical follow-up, or is this prescription-only?
- What labs do you run before starting, and at what intervals afterwards?
- How is my dose decided, and how quickly does it escalate?
- Is the medication branded or compounded, and where is it sourced?
- What is the plan for maintaining muscle while I lose weight?
Our program runs on a weekly injection with monthly clinical check-ins, labs at appropriate intervals, and time set aside for nutrition and how you are actually feeling. Which medication we recommend is decided from your history.
Book a consultation and we'll look at your history together and explain which one we would reach for and why.
